It is indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with cisplatin and/or alkylating agent-based combination. It is not considered a first-line treatment, but it can be useful as salvage therapy. It also has the advantage of being less toxic than other drugs used for treating refractory ovarian cancer.
Altretamine
Ergotamine
Ebastine
Orciprenaline
Clemastine
Isoprenaline
Hexoprenaline
Eluxadoline